STOCK TITAN

180 Life Sciences Corp. - ATNF STOCK NEWS

Welcome to our dedicated page for 180 Life Sciences news (Ticker: ATNF), a resource for investors and traders seeking the latest updates and insights on 180 Life Sciences stock.

180 Life Sciences Corp. Common Stock (symbol: ATNF) represents a pioneering clinical-stage biotechnology company based in Menlo Park, California. The company focuses on developing innovative therapeutics to address unmet medical needs in chronic pain, inflammation, and fibrosis.

The company has several key product development platforms currently in Phase IIb/III clinical trials:

  • Fibrosis and Anti-TNF Platform: This platform targets the treatment of fibrosis and anti-tumor necrosis factors, a major cause of inflammation.
  • Synthetic Cannabidiol (CBD) Analogs Platform: This platform includes man-made derivatives of CBD designed to offer therapeutic benefits.
  • α7nAChR Platform: Focused on the alpha 7 nicotinic acetylcholine receptor, which plays a role in modulating inflammation and pain.

180 Life Sciences Corp. is committed to advancing its drug candidates through robust clinical trials and cutting-edge research. From addressing postoperative pain relief with orally absorbed CBD tablets to combating chronic inflammation and fibrosis, the company's innovative approach highlights its significance in the biotechnology landscape.

The company’s recent achievements include a notable presentation by Dr. Michael J. Alaia at the 2022 American Academy of Orthopaedic Surgeons Annual Meeting. The talk focused on the efficacy of CBD tablets for postoperative pain relief, showcasing the potential impact of 180 Life Sciences Corp.'s therapies.

For more information, investors can contact Jason Assad, Director of Investor Relations, at jassad@180lifesciences.com.

Rhea-AI Summary

PALO ALTO, Calif., Dec. 29, 2022 – 180 Life Sciences updates shareholders on clinical programs targeting Dupuytren’s disease, frozen shoulder, and postoperative delirium. A phase 2B trial on Dupuytren's showed promising results, with plans for a UK marketing authorization application targeted for mid-2023. The company is enhancing recruitment strategies for the frozen shoulder trial, while preparations for the postoperative delirium trial are on track. Despite ongoing litigation, the company believes it is in a stronger cash position following recent financing and a completed reverse stock split.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.86%
Tags
none
-
Rhea-AI Summary

180 Life Sciences Corp. (NASDAQ: ATNF) has completed a registered direct offering of 1,714,286 shares of common stock and accompanying warrants, raising approximately $6 million in gross proceeds. The offering was conducted with a healthcare-focused U.S. institutional investor at a purchase price of $3.50 per share. Proceeds from the offering will be allocated to research and development, including preparations for a marketing authorization application for Dupuytren’s contracture in the UK. The warrants are exercisable after six months and expire in five years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.52%
Tags
-
Rhea-AI Summary

180 Life Sciences Corp. (NASDAQ: ATNF) has announced a definitive agreement with a U.S. institutional investor to sell 1,714,286 shares and warrants to purchase up to 2,571,429 shares at a price of $3.50 per share. The offering is expected to close on or around December 22, 2022, with gross proceeds anticipated to be approximately $6 million. Funds from this offering will be directed towards research and development, a marketing authorization application, and general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.85%
Tags
Rhea-AI Summary

180 Life Sciences Corp. (NASDAQ: ATNF) announced a one-for-20 reverse stock split effective December 19, 2022, to comply with NASDAQ's minimum bid requirement of $1.00. The total shares will decrease from approximately 40.5 million to about 2.0 million. The reverse split will not affect the par value or authorized shares. All outstanding options and warrants will be adjusted accordingly. This action was approved by shareholders during a special meeting on December 15, 2022. The company remains focused on addressing unmet medical needs through its clinical programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.76%
Tags
none
-
Rhea-AI Summary

180 Life Sciences Corp. (NASDAQ: ATNF) met with the UK MHRA to discuss Dupuytren's disease treatment data on October 31, 2022. They provided information about nodule size and hardness as surrogate markers. The MHRA noted that reducing nodule size may not correlate with disease progression and requested supporting literature on adalimumab's clinical safety. CEO Dr. James Woody stated they plan to submit a marketing approval application in 2023, though approval is not guaranteed. The company addresses significant unmet medical needs in Dupuytren's disease, impacting approximately 4% of the Western population.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.86%
Tags
none
Rhea-AI Summary

180 Life Sciences Corp. (NASDAQ: ATNF) announced positive findings from a study by Oxford researchers indicating that anti-TNF treatment (adalimumab) is likely cost-effective for early-stage Dupuytren's disease, impacting over 5 million people in the UK. The study, led by Professor Jagdeep Nanchahal, revealed that adalimumab significantly reduces disease symptoms and may cost £14,593 per QALY gained, below the NHS threshold of £20,000. Dr. James Woody emphasized the importance of these findings for potential market accessibility and ongoing partnership discussions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.86%
Tags
none
-
Rhea-AI Summary

180 Life Sciences Corp. (NASDAQ: ATNF), a clinical-stage biotechnology firm, provided an update to stockholders highlighting progress in its clinical development programs targeting Dupuytren’s disease and other conditions. The company is conducting Phase 2 trials, with promising data reported in The Lancet Rheumatology about anti-TNF therapy potentially preventing disease progression. A meeting with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) is scheduled for Q4 2022 to discuss regulatory pathways for Dupuytren’s therapy. The company is also advancing trials for frozen shoulder and postoperative cognitive delirium.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.45%
Tags
none
-
Rhea-AI Summary

180 Life Sciences Corp. (NASDAQ: ATNF) has announced the randomization of the first patient in a clinical trial evaluating the use of anti-tumor necrosis factor (TNF) therapy for pain predominant frozen shoulder. This significant milestone is part of a study funded by the National Institute of Health and Care Research in the U.K. The trial aims to assess whether early injections of anti-TNF can alleviate pain and prevent disease progression. Led by the University of Oxford, the study may pave the way for future phase 3 trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.53%
Tags
none
Rhea-AI Summary

180 Life Sciences Corp. (NASDAQ: ATNF) announced a grant from the U.K.'s National Institute for Health and Care Research for a feasibility trial exploring anti-TNF therapy to mitigate post-operative delirium in hip fracture patients aged 60 and over. The trial, led by researchers at the University of Oxford, aims to evaluate the effectiveness of anti-TNF therapy during surgery. Jointly funded by the NIHR and 180 Life Sciences, the trial is expected to begin enrollment in early 2023. This collaboration aims to address a critical unmet medical need, considering the high prevalence of post-operative delirium among older patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags

FAQ

What is the current stock price of 180 Life Sciences (ATNF)?

The current stock price of 180 Life Sciences (ATNF) is $1.86 as of December 20, 2024.

What is the market cap of 180 Life Sciences (ATNF)?

The market cap of 180 Life Sciences (ATNF) is approximately 3.9M.

What does 180 Life Sciences Corp. specialize in?

180 Life Sciences Corp. specializes in developing therapeutics for chronic pain, inflammation, and fibrosis.

Where is 180 Life Sciences Corp. headquartered?

The company is headquartered in Menlo Park, California.

What are the key platforms of 180 Life Sciences Corp.?

The key platforms are the Fibrosis and Anti-TNF Platform, Synthetic Cannabidiol (CBD) Analogs Platform, and the α7nAChR Platform.

What stage are the company's product development platforms in?

The platforms are currently in Phase IIb/III clinical trials.

Who can be contacted for investor relations?

Investors can contact Jason Assad, Director of Investor Relations, at jassad@180lifesciences.com.

What is the focus of the recent talk presented by Dr. Michael J. Alaia?

Dr. Alaia's talk focused on the efficacy of an orally absorbed CBD tablet for postoperative pain relief following rotator cuff surgery.

What is the company's ticker symbol?

The ticker symbol for 180 Life Sciences Corp. is ATNF.

What unmet medical needs does 180 Life Sciences Corp. aim to address?

The company aims to address unmet needs in chronic pain, inflammation, and fibrosis.

What is the significance of the α7nAChR platform?

The α7nAChR platform focuses on the alpha 7 nicotinic acetylcholine receptor, which is important in modulating inflammation and pain.

How can I stay updated with the latest news about 180 Life Sciences Corp.?

You can stay updated by checking the latest news on the company's official website or contacting their investor relations.

180 Life Sciences Corp.

Nasdaq:ATNF

ATNF Rankings

ATNF Stock Data

3.91M
1.89M
4.34%
3.45%
13.58%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
PALO ALTO